Clinical Report: Expression Levels of DCTN2 and PAX8 in Prostate Cancer Tissues
Overview
This study investigates the expression levels of DCTN2 and PAX8 in prostate cancer tissues and their correlation with clinicopathological characteristics and prognosis.
Background
Prostate cancer (PCa) is a prevalent malignancy among men, with increasing incidence and mortality rates. Understanding biomarkers related to PCa can aid in elucidating its pathogenesis and identifying potential therapeutic targets. The study focuses on DCTN2 and PAX8, which may serve as indicators of tumor characteristics and patient outcomes.
Data Highlights
Parameter
Findings
Positive Expression Rates
Higher in PCa tissues than adjacent tissues (P<0.05)
Association with Clinicopathological Features
Significant correlation with tumor differentiation, lymph node metastasis, clinical stage, distant metastasis, preoperative PSA, and Gleason score (P<0.05)
3-Year Progression-Free Survival Rate
Lower in positive DCTN2 and PAX8 expression (P = 0.002)
Prognostic Factors
Lymph node metastasis, clinical stage, Gleason score, DCTN2 and PAX8 expression were linked to poor prognosis (P<0.05)
Key Findings
Positive expression rates of DCTN2 and PAX8 are elevated in PCa tissues.
Both markers are significantly associated with various clinicopathological features.
Higher expression of DCTN2 and PAX8 correlates with lower 3-year progression-free survival rates.
Factors affecting prognosis include tumor differentiation, lymph node metastasis, clinical stage, and Gleason score.
Clinical Implications
The findings indicate that DCTN2 and PAX8 are associated with clinicopathological features and prognosis in prostate cancer patients.
Conclusion
DCTN2 and PAX8 expression levels in prostate cancer tissues are associated with significant clinicopathological features and prognosis.
